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Abstract
Background: Pulmonary arterial hypertension (PAH) in patients with systemic sclerosis is associated with a poor 
prognosis, but this can be improved by early disease detection. Abnormal pulmonary and cardiac function can be 
detected early by means of echocardiography, whereas right heart catheterization is usually performed later.
Objectives: The purpose of this prospective study was to detect early the presence of pulmonary artery vasculopathy 
in patients with verified systemic sclerosis without significant pulmonary fibrosis, normal lung volumes and a mildly 
reduced lung diffusion capacity of carbon monoxide (DLCO).
Methods: Nineteen consecutive female NYHA class I-II patients with scleroderma and a PAPs of < 35 mm/Hg measured 
by echocardiography, were enrolled between September 2007 and September 2009. They had a mean age of 51 ± 13 
years, body mass index of 25 ± 5 kg/m2). They all underwent complete Doppler echocardiography, CPET, a pulmonary 
ventilation test (carbon monoxide lung diffusion, DLCO), HRCT. To investigate PAH by means of complete resting 
Doppler echocardiography estimates of systolic pulmonary artery pressure (PAPs) derived from tr icuspid regurgitation, 
mean PAP derived from pulmonary regurgitation, pulmonary vessel resistance (PVR) derived from the acceleration time 
of the pulmonary outflow tract (ACTpo), and right ventricular function derived from tricuspid annular plane systolic 
excursion (TAPSE). Right heart catheterisation was conducted only, if pulmonary hypertension was suggested by 
echocardiography and an abnormal ventilator test.
The data are given as mean values ± SD, unless otherwise stated. The correlations between the variables were analysed 
using Pearson's r coefficient, and the predictive value of the variables was calculated using linear regression analysis. A 
p value of > 0.05 was considered significant.
Results: Right heart catheterization detected PAH in 15/19 patients; mean PAP was 30.5 mm/Hg and RVP 3.6 UW. 
Coronary angiography of the patients aged more than 55 years showed some evidence of significant coronary artery 
disease. Echocardiography showed high systolic PAP values (46 ± 8 mmHg), whereas right ventricular function was 
normal (TAPSE 23 ± 3 mm), and in line with the NYHA class. ACTpo was reduced in the patients with a systolic PAP of < 
46 mm/Hg (p > 0.001) and positively correlated with DLCO (p > 0.001) and the hemodynamic data.
There was a good correlation between ACTpo and PVR (hemodynamic data) (r = -0615; p > 0.01).
Conclusions: Although they need to be confirmed by studies of larger series of patients, our findings suggest that, in 
comparison with hemodynamic data, non-invasive echocardiographic measurements are an excellent means of 
identifying early-stage PAH.
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Introduction
Systemic sclerosis is a chronic disease essentially due to
microvascular abnormalities, antibodies and a fibroblast
production that leads to excessive collagen levels, and
skin and viscera fibrosis[1-3].
The most recent data show that the prevalence of sys-
temic sclerosis from 1977 to 1980 was 12.6-25/100,000,
with an incidence of 0.06-1.9/100,000. The recorded
mean age of the patients at the time of onset is between
45 and 65 years, this data does not reflect the real age as
the symptoms may appear many years before the first
specialist assessment. The main pulmonary complica-
tions are pulmonary fibrosis and pulmonary arterial
hypertension (PAH): interstitial lung disease is observed
in 70% of the patients with diffused systemic sclerosis,
and pulmonary hypertension in 35% of those with limited
systemic sclerosis[4,5]. The patients have no symptoms at
rest during the initial stages of the disease, but soon
develop slight dyspnea during physical exercise or rest;
some may also experience chest pain, asthenia and loss of
conscience under stress.
As pulmonary hypertension in systemic sclerosis may
not only be due to PAH, but also to interstitial lung dis-
ease and cardiac involvement[6-9], it is very important to
classify it adequately[10,11] in order to determine the
best treatment. According to the 2009 guidelines[12],
PAH describes an increase in mean pulmony artery pres-
sure (PAPm) to more than 25 mmHg. Echocardiography
and respiratory function testing are recommended every
year, even if the patient is asymptomatic, and right heart
catheterisation is usually performed in late stages.
The published frequencies of PAH in systemic sclerosis
vary widely (from 5% to 35%), depending on the study
population, and diagnostic methods (cardiac echo-Dop-
pler or right heart catheterisation) and criteria. Echocar-
diography plays a central role in the non-invasive
screening and management of patients with suspected
PAH as it guarantees the early identification and treat-
ment of a condition that is usually diagnosed at least two
or three years after its onset[13-15].
PAH and interstitial lung disease are the leading causes
of death in systemic sclerosis and, as their early detection
and treatment should improve morbidity and mortal-
ity[16,17]. The aim of this prospective study was to detect
the presence of pulmonary artery vasculopathy early in
patients with verified systemic sclerosis and normal lung
volumes, no significant pulmonary fibrosis, and mildly
reduced lung carbon monoxide diffusing capacity
(DLCO) by: 1) evaluating resting pulmonary function at
rest, and maximum and sub-maximum exercise capacity;
2) detecting systolic pulmonary artery pressure (PAPs)
values of < 35 mmHg using thoracic echocardiography;
and 3) investigating the relationships between PAP and
the acceleration time of the pulmonary outflow tract
(ACTpo), right ventricular function (tricuspid annular
plane systolic excursion; TAPSE), and right heart cathe-
terisation (PAPs, PAPm and pulmonary vessel resistance
[PVR]).
Patients and Methods
19 female patients, aged between 28 and 75 (51 ± 13);
BMI (Kg/m2) 25 ± 5, NYHA class I^-II^ diagnosed with
Systemic Sclerosis were enrolled between 2007 and 2009
in collaboration with the Rheumatic Department of the
University Hospital of Parma (EULAR Scleroderma Trials
criteria)[18].
All patients had standard pulmonary function tests,
including FVC and DLCO; auto-antibodies (ANA)
including anti-centromere, anti-Scl-70 were performed as
available from commercial laboratories.
A chest radiograph and a high resolution CT scan
(HCRT) were performed to select patients without signif-
icant pulmonary fibrosis.
Patients without significant pulmonary fibrosis with
reduced lung volumes, left heart dysfunction and signifi-
cant valvular disease were enrolled. [see Additional file 1]
ECG: rhythm, heart rate and strain in the right ventricle
Doppler echocardiography
The investigated echocardiographic parameters were
PAPs (derived from a tricuspid regurgitation flow value of
< 2.8 m/s), ACTpo (normal value < 130 msc), PVR (using
the equation: PVR = TRV/TVI rvot × 10+0.16)[19], infe-
rior vena cava flow, diameter and inspiratory changes
(normal value > 18 mm with respiratory collapse < 50%),
and Doppler tissue imaging (DTI) of the tricuspid annu-
lus, which were evaluated using a Phillips IE33 echocar-
diograph equipped with 2.5 and 3.5 MHz electronic
transducers, harmonic imaging and DTI.
Respiratory function
Respiratory function was tested in accordance with inter-
national recommendations using a pneumotachograph
and plethysmographic cabin connected to a computer for
data analysis (Vmax 22 and 6200, Sensor Medics, Yorba
Linda, CA)[20,21].
The analysed parameters were total lung capacity
(TLC), volume residue (VR), forced expiratory volume in
one second (FEV1), and the FEV1/FVC ratio. DLCO was
calculated using the single breath method, and the test
was only considered valid when the inspiratory volume
was the same as at least 90% of FVC. Each variable was
measured at least three times. The theoretical lung vol-
ume and DLCO values were obtained using the Quanjer
and Cotes regression equations[22].Serra et al. Cardiovascular Ultrasound 2010, 8:25
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Six-minute walking test
The six-minute walking test (6MWT) consists of walking
along a 30-metre corridor for the longest distance possi-
ble in six minutes using a standard protocol; as the test is
symptom-limited, the patients are allowed to stop and
resume walking when they wish. Before and after the test,
the patients' vital parameters were recorded and the
patients complete a visual analogue scale (VAS) quantify-
i n g  t h e  d e g r e e  o f  d i s p n e a .  O x y g e n  s a t u r a t i o n  ( S P O 2,
expressed as a percentage) and heart rate (HR, expressed
as beats per minute [bpm]) were continuously monitored
and recorded every 10 seconds from five minutes before
the walk to five minutes after returning to baseline values
using a portable pulsometer (Model 920 M, Healthdyne,
Marietta, GA). To allow for the learning effect, a pause of
60 minutes was allowed between each test.
Cardiopulmonary exercise test
A cardiopulmonary exercise test CPET) was performed
following a standardised procedure (ATS/ACCP State-
ment, 2003)[23]. After the oxygen and carbon dioxide
analysers and the flow mass sensor had been calibrated,
the study patients were asked to sit on an electromagneti-
cally braked cycle ergometer (Corival PB, Lobe BV, Gron-
ingen, The Netherlands) for a 3-minute rest period, with
the saddle adjusted to avoid maximum extension of the
knee. Exercising began with a 3-minute warm-up period
at 0 watts, followed by a progressively increasing ramp
protocol of 5-15 watts/min (depending on the anthropo-
metric data and the patients' degree of functional impair-
ment) for a period of 8-12 minutes. The patients were
required to maintain a pedalling frequency of 60 rpm, as
indicated by a digital display on the monitor of the
ergometer.
During the test, breath-by-breath VO2 (mL/min), car-
bon dioxide production (VCO2, mL/min) and minute
ventilation (VE, L/min) were collected (Vmax 229, Sensor
Medics, Yorba Linda, CA), the patients were continuously
monitored by means of a 12-lead electrocardiogram
(Corina, GE Medical Systems IT Inc., Milwaukee, WI)
and pulse oximeter (Pulse Oximeter 8600, Nonin Medical
Inc., MN), and blood pressure was measured at two-min-
ute intervals. Resting end-tidal CO2  pressure (rest
PETCO2, mm Hg) was recorded as the mean value mea-
sured during the 3-minute rest period, and peak VO2 as
the mean value during the last 20 seconds of the test
(expressed in mL/min and mL/kg/min). Ventilatory
response to exercise was calculated as a linear regression
function by plotting VE against VCO2 every 10 seconds of
exercise (VE/VCO2 slope).
Right heart catheterisation
The patients aged more than 55 years underwent femoral
right heart catheterisation using a 7F catheter thermo
dilution, to evaluate systolic, mean and capillary pulmo-
nary pressure and calculate the trans-pulmonary gradient
(GTP = PAPm/CO), PVR (dynes.scm-5 = GTP/CO × 80)
and cardiac output (CO). PAH was defined as a PAPm of
< 25 mm/Hg and Pulmonary Capillary Wedge Pressure
(PCWP) of > 15 mm/Hg. Measuring the pressure of the
pulmonary occlusion makes it possible to identify the
pulmonary pressure site and allows the diagnosis of the
pulmonary hypertension site (pre-/post-capillary).
Statistical analysis
The primary objectives were to assess the associations
between DLCO% at rest and PAP, and between the
echocardiographic and right heart catheterisation mea-
surements of PVR. All of the data are given as mean val-
ues ± SD unless otherwise stated. Pearson's correlation
coefficient and Bland-Altman analysis were used to com-
pare PAPs, ACTpo and TAPSE with DLCO, VO2max%,
VE/VCO2, O2 pulse, NYHA class and PVR. Stepwise for-
ward multiple regression analysis allowed the weighting
of the independent effects of the potential determinants
on an independent variable. The null hypothesis was
rejected when p was > 0.05.
ACTpo was measured by two echocardiographers
blinded to the clinical data in order to assess interob-
server variability.
Results
Seventeen of the 19 patients had limited cutaneous sys-
temic sclerosis, and two an overlap syndrome including
scleroderma.
Pulmonary function data
The patients were selected because the results of respira-
tory function testing at rest (FVC/DLCO) aroused a sus-
picion of pulmonary vasculopathy (Tab 1). Flow, volume
were normal, but not DLCO (71% of the theoretical
value) and FV/DLCO (1.5). The distance covered in the
6MWT was normal (424 ± 102 m) (Tab 2). During the
cardiopulmonary test, there was a moderate reduction in
exercise capacity (VO2max% theoretical 68 ± 14%), a
reduction in oxygen pulse (8.1 ± 1.7 ml/beat), and a
reduction in the equivalent CO2 ventilators (VE/VCO2
slope 38 ± 12) (Tab 3).
Echocardiography
Systolic pulmonary pressure was high (46 ± 8 mmHg),
but right ventricular function was normal (TAPSE 23 ±
3), and in line with the patients' NYHA class (Tab. 4).
In the patients with high PAPs, echocardiography
showed a reduction in acceleration time on the pulmo-
nary flow velocity curve (ACTpo 121 msc) (p > 0.001)
that corresponded with the diffusion capacity at rest
(DLCO%).Serra et al. Cardiovascular Ultrasound 2010, 8:25
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Mean ACTpo and PVR were respectively 117 msc and
3.31 UW.
There was a significant correlation between PAPs and
NYHA class (r = 069; p > 0.05), between TAPSE and
NYHA class (r = -0.47; p > 0.05), and between DLCO and
peak VO2 (p > 0.05), and a good correlation between
ACTpo and NYHA class (r = - 0.71; p > 0.001). [see Addi-
tional file 2]
Right heart catheterisation
Right heart catheterisation detected PAH in 15/19
patients, and one patient had veno-occlusive pulmonary
hypertension; PAPm was 30.5 mmHg and PVR 3.6 UW.
There was a good correlation between ACTpo and PVR
(r = - 0615; p > 0.01) (Fig 1).
Coronary angiography (carried out in the patients aged
< 55 years) did not reveal any signs of significant coronary
artery disease.
Discussion
Pulmonary artery hypertension is the most frequent
cause of death in scleroderma patients, and its early iden-
tification is the best means of improving survival.
By allowing a non-invasive evaluation of the right
atrium ventricular gradient, post-systolic tricuspid annu-
lar movement (TAPSE) and the acceleration time of right
outflow (ACTpo, an indirect marker of pulmonary vascu-
lar resistance), echocardiography reveals the presence of
pulmonary hypertension even in patients in a less
Table 1: The functional respiratory values at rest (flow, 
volume, MIP and MEP) were normal except DLCO (71% ± 
theoretical) and FV/DLCO (1,5)
DATA  Mean ± SD 
Age (y ±) 54 ± 11
BMI (Kg/m2) 25 ± 5
FEV1 (L) 2,47 ± 0,60
FEV1 (% theoretical) 106 ± 26
FEV1/SVC (%) 81 ± 3
TLC (% theoretical) 97 ± 20
FVC (% theoretical) 102 ± 18
DLCO (% theoretical) 71 ± 18
FVC/DLCO 1,5 ± 0,4
Table 2: The 6MWT showed a normal range test (424 +-102 
m)
Parameter  Mean ± SD 
Distance (meter) 424 ± 102
Distance(% theoretical) 122 ± 12
Oxigen Hemoglobinic 
Desaturation (%)
2 ± 3
Table 3: CPET showed: VO2 max % theoretical (68 ± 14), a 
reduction in the oxygen pulse (8,1 ± 1,7) and the 
equivalent CO2 ventilators (VE/VCO2 slope 38 ± 12)
Parameter  Mean ± SD 
V'O2max (ml/kg/min) 19,9 ± 7,1 
V'O2max (L/min) 1,18 ± 0,34 
V'O2max (% theoretical) 63 ± 14 
V'O2@AT (l/min) 0,90 ± 0,26 
V'O2@AT (ml/kg/min) 14,6 ± 5,5 
Watts 75 ± 34 
(% theoretical) 77 ± 20 
V'O2/Watts 7,2 ± 2,7 
HR max (bmp) 146 ± 24 
HR (%) 88 ± 13 
O2 pulse (ml/bpm) 8,1 ± 1,7 
HR/VO2  66 ± 20 
VE max (%) 50 ± 20 
VE/VCO2 (slope) 38 ± 12 Serra et al. Cardiovascular Ultrasound 2010, 8:25
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advanced functional class. The data obtained by means of
invasive right heart catheterisation confirmed our
echocardiographic findings, which overestimated three
cases with tricuspid gradient values of > 3 m/sec [24-26].
Echocardiographic measurements of the tricuspid gra-
dient are accurate but may lead to overestimated pulmo-
nary pressures or, less frequently, underestimates due to
an incorrectly aligned regurgitated jet. Valchiery et al.
found a good correlation between invasive and non-inva-
sive (echocardiographic) measurements of PAPs (r = 0.57,
p > 0.001), but other authors have found discrepancies in
35% of cases[27]. The discrepancies are possibly due to
factors such as inexperience with the technique, an incor-
rectly aligned regurgitated jet (which can be better
defined using contrast medium), or incorrect right atria
pressure, which can be better evaluated using the diame-
ter and the collapse of the inferior vena cava during a
breath in.
According to the 2009 guidelines[12], PAH should not
be diagnosed by means of echocardiography alone. How-
ever, as it detected pulmonary vasculopathy early on the
basis of the ACTpo, TAPSE and PAPs findings, we believe
that the echocardiographic estimate of PVR should
become a part of a standard examination. Three-dimen-
sional echocardiography or cardiac magnetic resonance
may be useful in evaluating right ventricular function, but
neither were used in this study.
Echocardiography and CPET are both essential for
screening patients at risk of developing PAH, which in
any case needs to be confirmed by catheterisation, which
also provides prognostic data that are useful for thera-
peutic purpose[26-29].
Conclusions
The alterations in cardiorespiratory function described
above represent initial signs of pulmonary and cardiac
vessel impairment in patients with systemic sclerosis.
Echocardiographic findings non-invasively reveal the
presence of increased pulmonary pressure and pulmo-
nary vascular resistance, morphological changes, and
functional abnormalities in right ventricular parameters,
which cannot be identified by means of catheterisation.
The early recognition of vascular involvement together
with a multidisciplinary approach to the illness should
lead to better therapeutic results[30,31].
Study limitations
The main limitation of this study is the small number of
patients, and so the findings need to be confirmed in
larger series. Misalignment due to the equalisation of
pressure between the right atrium and ventricle may lead
to underestimated echocardiographic calculations of
PAPs and PVR, but we found a good level of inter-
observer agreement concerning tricuspid regurgitation
velocity and pulmonary outflow acceleration time (p >
0.5).
Consent
All patients provided written informed consent to partic-
ipate in the research
Additional material
Abbreviations
ACTPO: Pulmonary outflow acceleration time; BR: Breath reserve (MVV-VEmax);
CO: Cardiac Output; CPET: Cardio Pulmonary Exercise Test; DLCO: Carbon mon-
oxide lung diffusion.; FEV1: Forced expiratory volume in 1 second; FVC: Forced
vital capacity; GTP: Transpulmonary gradient (PAPm/CO); MVV: Maximum Vol-
untary Ventilation; NYHA: New York Heart Association; O2Pulse: Oxygen Pulse
Additional file 1 Patient's data. Seventeen of the 19 patients had limited 
cutaneous systemic sclerosis, and two an overlap syndrome including scle-
roderma.
Additional file 2 ECHO an RHC data. There was a significant correlation 
between TAPSE and NYHA class (r = -0.47; p > 0.05) and a good correlation 
between ACTpo and NYHA class (r = - 0.71; p > 0.001). Right heart catheter-
isation detected PAH in 15/19 patients: PAPm was 30.5 mmHg and PVR 3.6 
UW.
Table 4: Echo data showed high pulmonary systolic 
pressure values (46 ± 8 mmHg), while the right ventricular 
function was normal (TAPSE 23 ± 3)
Parameter  Mean ± SD 
NYHA (I-IV) II (I-II)*
PAPs (mm Hg) 46 ± 8
TAPSE (mm) 23 ± 3
ACTpo (msec) 117 ± 6
PVR (WU) 3.31 ± 2
Figure 1 Correlation between ACTpo and PVR (RHC).Serra et al. Cardiovascular Ultrasound 2010, 8:25
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(VO2/HR); PAH: Pulmonary Arterial Hypertension; PAPm: Pulmonary Artery
Pressure mean; PCWP: Pulmonary Capillary Wedge Pressure; PVR: Pulmonary
Vessel Resistance; RV: Residual Volume; SS: Systemic Sclerosis; TAPSE: Tricuspid
annular plane systolic excursion; TLC: Total Lung Capacity; VAS: -Visual analogic
Scale; VO2: Oxygen Consumption; VCO2: Carbon Dioxide production; VE/VCO2
slope: CO2 Ventilatory equivalent slope; VE/VO2 slope: O2 Ventilatory equiva-
lent slope; 6MWT: 6 Minute Walking Test.
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